MorphoSys AG buy Haans
Summary
This prediction ended on 12.04.16 with a price of €48.50. The prediction for MorphoSys AG disappointed with a performance of -14.24%. Haans has 50% into this predictionMorphoSys is a German biopharmaceutical company that develops innovative therapies for the treatment of cancer, autoimmune diseases, and other serious illnesses. The company specializes in developing monoclonal antibodies, which are highly specific and targeted therapies that recognize and bind to specific cancer cells or disease-causing proteins in the body. MorphoSys has a diverse pipeline of products in various stages of development, including several drugs that have shown promising results in clinical trials. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of over $4 billion.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
MorphoSys AG | - | - | - | - |
iShares Core DAX® | -1.114% | 3.430% | 25.966% | 25.039% |
iShares Nasdaq 100 | 1.816% | 6.911% | 30.390% | 48.139% |
iShares Nikkei 225® | 2.113% | 5.501% | 23.404% | 11.979% |
iShares S&P 500 | 2.038% | 5.327% | 30.881% | 46.982% |
Comments by Haans for this prediction
In the thread Morphosys AG diskutieren
Für mich ein Must Have im Bio-Tech-Sector
Die Aktie erscheint mir aus konsolidiert zu sein. Für 2016 stehen stehen viele News auf dem Plan, welche den Kurs deutlich in Richtung Norden treiben können.
Ein Stopp bei 54 Euro, welcher nach dem Bruch der 200 Tage-Linie nachgezogen werden kann, macht das Chance Risiko Verhältnis, diese Aktie zu einer erstklassigem Investment.
Jetzt nachkaufen....